Annie R. Abruzzo

Annie R. Abruzzo

Auto-generated profile, based on publicly available information

Annie R. Abruzzo

Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2023 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
CMCamille Mathey-Andrews
Camille Mathey-Andrews
AAAnnie R. Abruzzo
Annie R. Abruzzo
SVShivaek Venkateswaran
Shivaek Venkateswaran
APAlexandra L. Potter
Alexandra L. Potter
PSPriyanka Senthil
Priyanka Senthil
MLMichael Lanuti
Michael Lanuti

31 August 2024 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
AAAnnie R. Abruzzo
Annie R. Abruzzo
RBRebecca S. Beroukhim
Rebecca S. Beroukhim
SCSarah Campos
Sarah Campos
SGSunil Ghelani
Sunil Ghelani
CBChristopher W. Baird
Christopher W. Baird
SESitaram M. Emani
Sitaram M. Emani

30 October 2024 in JTCVS Open
Verified
Journal Article
Open access
AAAnnie R. Abruzzo
Annie R. Abruzzo
SMSiobhan McGurk
Siobhan McGurk
GTGeorge Tolis
George Tolis
SASary Aranki
Sary Aranki
ASAshraf Sabe
Ashraf Sabe
AAAkinobu Akinobu
Akinobu Akinobu
Patients with cancer who receive radiation therapy to the thorax often develop radiation-induced heart disease (RIHD) decades later. Previous chest radiation is associated with elevated perioperative risk of complications and mortality after cardiac surgery. Whether the type of valve (mechanical vs bioprosthetic) used affects outcomes in patients with RIHD is unknown. This retrospective review analyzed the characteristics and postoperative outcomes of patients with a previous history of chest radiation for Hodgkin or non-Hodgkin lymphoma who underwent surgical valve replacement at a single institution between 2000 and 2021. Both 30-day perioperative outcomes and long-term survival were assessed. Patients who received mechanical valve tended to be younger, have more valves replaced, and have undergone previous coronary artery bypass grafting than bioprosthetic valve recipients. Valve type alone did not alter perioperative complications or overall survival. Median survival was 11.0 years in mechanical and 10.9 years in bioprosthetic valve patients (P = .930). Twelve patients underwent valve reinterventions (6 mechanical, 6 bioprosthetic), and 3 underwent transplant. Single-valve (aortic valve or mitral valve) recipients fared better with median survival of 13.3 years compared with 6.2 years in those who underwent combined aortic valve replacement plus mitral valve replacement (P < .0001). Patients with RIHD who undergo surgical valve replacement have similarly suboptimal short- and long-term outcomes regardless of mechanical versus bioprosthetic valve type. Those who required combined aortic and mitral valve replacement had especially high 10-year overall mortality. Further investigation in a larger dataset including transcatheter approaches is warranted.

5 August 2025 in Oral Oncology
Verified
Journal Article
Closed access
AAAnnie R. Abruzzo
Annie R. Abruzzo
MHMiriam T.H. Harris
Miriam T.H. Harris
HSHerve Y. Sroussi
Herve Y. Sroussi
JSJoji Suzuki
Joji Suzuki
JKJason I. Kass
Jason I. Kass
EREleni M. Rettig
Eleni M. Rettig

17 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
AFAdam Fisch
Adam Fisch
AAAnnie R. Abruzzo
Annie R. Abruzzo
SESamuli Eldfors
Samuli Eldfors
DDDipon Das
Dipon Das
QWQin Wang
Qin Wang
DFDaniel Faden
Daniel Faden
Purpose: Human papillomavirus (HPV)–associated carcinomas (HPV+ cancers) account for 5% of all cancers. Circulating tumor HPV DNA (ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. Although HPV integration into the host genome is a proven tissue-based biomarker predicting poor clinical outcomes, existing clinically utilized ctHPVDNA assays cannot classify the viral physical state. Experimental Design: We previously developed HPV-DeepSeek, a multifeature HPV whole-genome sequencing liquid biopsy with 99% diagnostic accuracy at the time of HPV+ oropharyngeal cancer diagnosis. We tested the diagnostic accuracy of HPV-DeepSeek in a cohort of 235 HPV+ cancers across 9 anatomic sites and used a novel blood-based computational classifier to infer the HPV genome physical state from plasma, termed HPV sequencing-based integration analysis (HPV-SIGNAL), to assess its prognostic potential. Results: HPV-DeepSeek achieved 99% sensitivity and specificity. In 189 eligible samples, HPV-SIGNAL identified 4 viral physical states: episomal-only (n = 71), episomal-rearranged (n = 52), integrated-mixed (n = 57), and integrated-clonal (n = 9), which were confirmed and further elucidated via 3 orthogonal tissue and blood approaches. Patients harboring integrated viral states in blood exhibited significantly worse age-adjusted and American Joint Committee on Cancer stage–adjusted progression-free survival [PFS; HR, 2.78; 95% confidence interval (CI), 1.30–5.99; P = 0.009] and overall survival (OS; HR, 2.95; 95% CI, 1.01–8.61; P = 0.048) compared with patients with episomal states. Conclusions: HPV whole-genome sequencing liquid biopsy has high diagnostic accuracy across HPV+ cancer types and can be used to identify and classify HPV physical states from blood. Patients with integrated viral states detected in blood demonstrated worse PFS and OS, suggesting that blood-based HPV physical state classification could be used as a prognostic tool at the time of cancer diagnosis.

2 November 2026
Verified
Other
Open access
PDF file
AFAdam Fisch
Adam Fisch
AAAnnie R. Abruzzo
Annie R. Abruzzo
SESamuli Eldfors
Samuli Eldfors
DDDipon Das
Dipon Das
QWQin Wang
Qin Wang
DFDaniel Faden
Daniel Faden
Supplementary Figure S1. Exploration of HPV integration and rearrangement events using long-read sequencing